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ISCHEMIC HEART disease (IHD), also referred to as coronary artery disease (CAD) and atherosclerotic cardiovascular
disease, is the most prevalent cardiovascular illness in the western world and is responsible for significant morbidity and mortality.1-3 Recently published data from the Global Burden of
Diseases estimated that around 1.72% of the world’s population
(126 million individuals) were affected by IHD3 and that IHD
was the leading cause of death in 9 million people globally in
2017. In the United States, the prevalence of IHD is 2,929 per
100,000 individuals, and the World Heart Federation estimates
the cost per episode of IHD to be upward of $5,000.3
Due to the large territory at risk for myocardial ischemia,
left main coronary artery disease (LMCAD) presents with significant life-shortening morbidity and mortality.4 Traditionally, revascularization with coronary artery bypass grafting
(CABG) was the treatment of choice for patients with LMCAD
1
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and triple-vessel disease. However, significant advances in the
techniques and stents of percutaneous coronary intervention
(PCI) have made it a viable contender for revascularization in
patients based on their anatomic complexity. As such, several
trials, meta-analyses, single-center, and observational studies
recently have been published to evaluate the outcomes of
LMCAD patients undergoing PCI and/or CABG.
The authors here summarize and critically appraise key
clinical trials and other studies in the treatment of LMCAD.
Medical Management of LMCAD
The last few decades have seen a variety of newer-age disease-modifying drugs (such as statins, inhibitors of the reninangiotensin-aldosterone system, and antiplatelet agents, such
as P2Y12 inhibitors) that are effective in reducing adverse cardiovascular events in patients with CAD.5-11 However, most
of the randomized clinical trials (RCTs) that previously
defined the guidelines for the treatment of patients with
LMCAD were conducted in an era when medical therapy
largely was limited, and, as such, only a fraction of patients
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with “medically managed” LMCAD were put on drugs such as
beta-blockers and aspirin.12-14 Despite the dearth of evidencebased optimal medical therapy, the aforementioned RCTs
found favorable outcomes in lower-risk patients with LMCAD
(with <70% stenosis or with preserved left ventricular function) who were medically managed alone (66% survival at 3years). As such, lifestyle interventions and guideline-directed
secondary preventions should be encouraged in patients with
LMCAD, similar to how these are implemented in patients
with non-left main disease. There are, however, unmet clinical
challenges, such as differentiating between significant and
nonsignificant left main disease from angiographic and clinical
characteristics, that often make even the most experienced
physicians wary of deferring revascularization in favor of medical therapy. With the advent of newer invasive techniques,
such as intravascular ultrasound (IVUS) and fractional flow
reserve (FFR), cardiologists may be able to better tailor the
treatment aspects of patients with revascularization in conjunction with optimal medical therapy.
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in estimating the overall ischemic burden of the LM lesion. as
well as in improving the clinical outcomes of patients.19,20
However, the cut-off for the minimal luminal area for left
main lesions varies in different populations, and, as such, the
values ascribed to IVUS should be interpreted with caution.
The hemodynamic significance of an LM stenosis lesion is
best assessed by FFR. Studies have shown favorable long-term
outcomes with deferring revascularization in patients with
angiographically intermediate LM lesions with an FFR of
0.80.16 An LM lesion is assumed to be hemodynamically significant or insignificant if the FFR of the lesion is >0.85 or
0.80, respectively.21 However, for lesions with an FFR
between 0.81 and 0.84, the hemodynamic significance of the
lesion cannot be accurately determined, and as such, imaging
with IVUS is preferred in these cases.19,20 With all the tools
that are available, both IVUS and FFR complement the angiographic findings in the evaluation of an LM lesion.22
Current Guidelines

Evaluation of LMCAD
Although patients with significant LMCA stenosis usually
are symptomatic, it is not uncommon for significant LMCAD
to be found incidentally in stable patients undergoing coronary
angiography.14 While there is significant interobserver variability in visually assessing intermediate LM stenoses (30%70%), the angiographic assessment of LM stenosis 70% is
fairly accurate and reproducible.15,16 In order to mitigate the
unwarranted risks from premature CABG in noncritical
lesions, it is imperative to use noninvasive and/or invasive
modalities to evaluate LMCA stenosis in conjunction with
angiography.16,17 From a noninvasive standpoint, certain features are highly indicative of significant LM or equivalent disease, including (1) Duke treadmill score 11, (2) stressinduced sustained ventricular tachyarrhythmia or nonsustained
ventricular tachyarrhythmia >30 seconds or ST-segment elevation, (3) exercise left ventricular ejection fraction (LVEF)
35%, (4) large reversible anterior perfusion defect (10%
left ventricular involvement on nuclear perfusion or 12.5%
left ventricular involvement on cardiac magnetic resonance
imaging) or multiple reversible perfusion defects of moderate
size, (5) stress-induced left ventricular dilation or increased
lung uptake in the setting of moderate perfusion defect or large
fixed perfusion defect, (6) echocardiographic wall motion
abnormality involving >2 segments developing at low-dose
dobutamine (10 mg/kg/min) or at a low heart rate (<120
beats/min).18 Invasively, while tools like IVUS help in
describing the anatomic extent of the LM lesion, the hemodynamic significance of a clinically unclear LM stenosis lesion is
best evaluated by pressure wire assessment of FFR. Intracoronary imaging with IVUS is helpful in describing the anatomic
extent of the disease, determination of plaque extent, as well
as in determining ostial involvement of daughter branches. In
patients with distal lesions and those treated with a 2-stent
strategy, IVUS also helps in ensuring the optimum expansion
and apposition of stents after LM PCI. IVUS, thus, is helpful

The current guidelines base the method of revascularization
in patients with LMCAD on the anatomic complexity of the
coronary artery disease (SYNTAX score) and the surgical risk
of the patients.4 The recommendations come largely on the
basis of the results of the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX)
trial23-25 and smaller underpowered studies.23-26 In the United
States, the existing American College of Cardiology (ACC)/
American Heart Association (AHA) clinical guidelines continue to champion CABG as a Class I indication for myocardial revascularization in patients with LMCAD with
coexisting complex multivessel disease (SYNTAX score
33).27 PCI, on the other hand, has a Class IIa recommendation in patients with increased surgical bypass risk with isolated LM stenosis involving the ostium or shaft and without
coexisting multivessel disease. For patients with LM stenosis
involving the distal bifurcation or with a low or intermediate
SYNTAX score (32) and at an elevated surgical risk, PCI
has a Class IIb indication (“may be reasonable”). The current
European Society of Cardiology/European Association for
Cardio-Thoracic Surgery (ESC/EACTS) guidelines have a
Class I recommendation for PCI in patients with low anatomic
complexity, a Class IIa recommendation for patients with
intermediate anatomic complexity, and a Class III recommendation for patients with high anatomic complexity (Table 1).28
Review of RCTs
SYNTAX Trial
The first results that largely defined the recommendation of
CABG for left main CAD based on SYNTAX scores came
from the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial.23-25
This trial formed the core of all major cardiology and cardiothoracic surgery societal guideline recommendations.
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Table 1
Guidelines for the Type of Revascularization in Patients With Left Main Coronary Artery Disease
ACC/AHA Guidelines (2011)27
Class* (Levely) Recommendation
CABG recommended to improve survival in patients with 50% diameter stenosis of left main coronary artery
PCI is a reasonable alternative to CABG to improve survival in patients with 50% diameter stenosis of left main coronary artery with:
 Low SYNTAX score 22 (ostial or trunk LMCAD)
and
 STS surgical risk score 5%
IIa
B
PCI is reasonable to improve survival in patients with UA/NSTEMI when an unprotected left main coronary artery is the culprit lesion and
the patient is not a candidate for CABG
IIa
C
PCI to improve survival is reasonable in patients with acute STEMI when an unprotected left main coronary artery is the culprit lesion, distal
coronary flow is less than TIMI grade 3, and PCI can be performed more rapidly and safely than CABG
IIb
B
PCI may be reasonable to improve survival in patients with 50% diameter stenosis of left main coronary artery with:
 Low-intermediate SYNTAX score <33 (bifurcation LMCAD), and
 STS surgical risk score >2%,
III
B
PCI to improve survival should not be performed in stable patients with 50% diameter stenosis of left main coronary artery with unfavorable
anatomy for PCI and who are good candidates for CABG
ESC/EACTS Guidelines28
I
A
For CABG
I
A
For PCI
LMCAD with Low SYNTAX score (0-22)
I
A
For CABG
IIa
A
For PCI
LMCAD with Intermediate SYNTAX score (23-32)
I
A
For CABG
LMCAD with High SYNTAX score (33)z
III
B
For PCI

I
IIa

B
B

NOTE. SYNTAX score calculation information is available at http://www.syntaxscore.com
Abbreviations: ACC/AHA, American College of Cardiology/American Heart Association; ESC/EACTS, European Society of Cardiology/European Association
for Cardio-Thoracic Surgery; LMCAD, left main coronary artery disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; STS
risk score, Society of Thoracic Surgeons-predicted risk of operative mortality; STEMI, ST-elevation myocardial infarction; SYNTAX, Synergy between
Percutaneous Coronary intervention with TAXUX and Cardiac surgery; TIMI, thrombolysis in myocardial infarction; UA/NSTEMI, unstable angina/non-STelevation myocardial infarction.
* Class of recommendation.
y Level of evidence.
z PCI should be considered if Heart Team is concerned about the surgical risk or if the patient refuses CABG after adequate counselling by the Heart Team.

The SYNTAX trial was a prospective, multinational trial
conducted in 85 centers across the United States and Europe
between 2005 and 2007, in which 1,800 patients with de novo
left main or 3-vessel disease were randomly assigned to
undergo CABG or PCI with first-generation paclitaxel-eluting
stents. Patients were grouped not only based on the number of
stenotic vessels, but also on their SYNTAX scores. Patients
undergoing PCI were prescribed antiplatelet medications as
per directions for the use of the Taxus Express stent and local
clinical practice. All patients who underwent randomization
were indefinitely prescribed aspirin.
The primary endpoint of the trial was a composite of major
cardiovascular or cerebrovascular events (MACCE), including
all-cause mortality, stroke, myocardial infarction (MI), and the
need for repeat revascularization at 12 months after randomization. At 1 year, patients undergoing CABG and PCI had similar rates of MACCE (13.7% v 15.8% respectively; p = 0.44).
While the rate of repeat revascularization was significantly
higher in patients who underwent PCI (11.8% v 6.5% for
CABG; p = 0.02), the stroke rate was higher in the CABG
group (2.7% v 0.3% for PCI; p = 0.01).
For patients with LMCAD, the results from the 5-year analysis of this trial not only confirmed the results at 1 year but
also demonstrated significant advantage of CABG in the hard
components of the composite endpoint; namely, death, stroke,

and MI in patients with LM.25 In patients with LMCAD, while
the MACCE rate was numerically higher in patients who
received PCI as compared to CABG, it did not meet statistical
significance (36.9% v 31%; hazard ratio [HR] 1.23 [95% confidence interval (CI), 0.95-1.59]; p = 0.12). Additionally, the
composite safety endpoint of death/stroke/MI was not significantly different between the 2 treatment strategies (PCI v
CABG, 19% v 20.8%; HR 0.91 [95% CI, 0.65-1.27];
p = 0.57). Further, stroke rates were significantly higher in
patients in the CABG group (4.3% v 1.5% for PCI; HR 0.33
[95% CI 0.12-0.92]; p = 0.03), while the rate of repeat revascularization was greater in patients randomized to the PCI group
(26.7% v 15.5% for CABG; HR 1.82 [95% CI, 1.28-2.57]; p <
0.01). When stratified by the baseline SYNTAX scores,
patients with a higher SYNTAX score (33) undergoing
CABG had lower incidences of MACCE (29.7% v 46.5% for
PCI; HR 1.78 [95% CI 1.21-2.63]; p = 0.003), cardiac death
(5.9% v 15.8% for PCI; HR 2.98; [95% CI, 1.32-6.73];
p = 0.006), revascularization (11.6% v 34.1% for PCI; HR
3.30 [95% CI 1.86-5.88; p < 0.001), and MI (6.1% v 11.7%
for PCI; HR 1.88 [95% CI 0.82-4.30]; p = 0.13). On the other
hand, patients undergoing CABG had a higher incidence of
stroke (4.9% v 1.6% for PCI; HR 0.32 [95% CI 0.07-1.54];
p = 0.13). The 10-year follow-up results of this trial recently
were published by the SYNTAX Extended Survival study
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investigators based on data from 1,689 (94%) patients, out of
whom 705 had LMCAD.29,30 At 10 years, there was no significant difference in all cause deaths between patients with
LMCAD undergoing PCI versus CABG (27% v 28%, respectively; HR 0.92, [95% CI 0.69-1.22]).
A major limitation of this trial was that it was powered
toward patients with intermediate and high SYNTAX scores.
Additionally, PCI was performed with first-generation paclitaxel-eluting stents; newer generation drug-eluting stents
(DES) have been shown to be associated with significantly
improved outcomes.31,32
LE MANS Trial
The 10-year outcomes of the Left Main Coronary Artery
Stenting (LE MANS) trials were published in 2016.33 The LE
MANS trial was the first prospective study to evaluate left
main stenting and CABG for unprotected LM stenosis with
low and medium complexity of coexisting CAD according to
SYNTAX score. The trial enrolled 105 symptomatic patients
with documented myocardial ischemia, with at least 50% stenosis of the unprotected LM coronary artery. Exclusion criteria
were patients with acute MI, total occlusion of the LM, comorbid conditions, or coronary anatomic considerations that
increased the surgical risk to a EuroSCORE of 8 or more,
stroke (or transient ischemic attack) within 3 months, renal
dysfunction, or contraindication to antiplatelet therapy.34
Patients were randomized to receive either PCI or CABG. For
patients undergoing PCI, medical therapy with aspirin and a
thienopyridine (clopidogrel or ticlopidine) was started at least
2 days before the procedure, with unfractionated heparin being
given in standard doses. Intravenous glycoprotein IIb/IIIa
blockers were used in patients with complex coronary lesions
and unstable angina. All patients undergoing surgical revascularization were prescribed antiplatelet therapy for at least 12
months after the procedure. The primary endpoint of the LE
MANS trial was LVEF assessed by 2-dimensional echocardiography at 1 year. At 10 years, there was a trend toward higher
LVEF with PCI compared to CABG 54.9 § 8.3% v 49.8 §
10.3%; p = 0.07). Although not statistically significant, the
incidence of MACCE was lower in the PCI group in comparison to the CABG group (52.2% v 62.5%; p = 0.42). There was
a trend toward higher very long-term MACCE-free survival in
the PCI group (HR: 1.57; 95% CI: 0.90-2.73; p = 0.10). The
results were similar in favoring PCI over CABG with regard to
the incidence of MI, long-term MI survival, and stroke and/or
transient ischemic attack, with the analysis not reaching statistical significance. Of note, the need for repeated revascularizations was similar between both groups (HR: 1.34; 95% CI:
0.61-2.95; p = 0.46).
The study showed equipoise between LM stenting and
CABG. However, this study was underpowered to provide
conclusive answers,26 and the authors concluded that PCI provided numerically, but statistically nonsignificant, favorable
long-term outcomes up to 10 years over CABG in patients
with unprotected LM coronary artery stenosis with low and
medium complexity of coexisting CAD. It is also important to
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note that only 35% of stents implanted in the trial were DES,
whereas >80% of patients received arterial bypass grafts. This
created a difference in the quality of revascularization, and the
data are not representative of contemporary PCI strategy with
new-generation DES.
PRECOMBAT
The Premier of Randomized Comparison of Bypass Surgery
versus Angioplasty Using Sirolimus-Eluting Stent in Patients
with Left Main Coronary Artery Disease (PRECOMBAT) trial
was a noninferiority trial in which 600 patients with unprotected left main coronary artery disease were randomized to
undergo PCI with a sirolimus-eluting stent or CABG, in Korea,
from April 2004 to August 2009.30,35
Patients with a left main coronary artery stenosis of >50%
(estimated visually) and with a diagnosis of stable angina,
unstable angina, silent ischemia, or non-ST-segment elevation
MI, were included in this study. All patients undergoing PCI
were prescribed aspirin plus clopidogrel (loading dose, 300
mg) or ticlopidine (loading dose, 500 mg) before or during the
procedure. Postprocedurally, patients were prescribed
100 mg/d aspirin indefinitely, and 75 mg/d clopidogrel, or
250 mg/d ticlopidine for at least 6 months. The primary endpoint was the incidence of MACCE (composite of death from
any cause, MI, stroke, or ischemia-driven target-vessel revascularization). The mean age of the enrolled patients was 62.3
§ 9.7 years, with 76% being males. The mean SYNTAX score
was 24.8 § 10.3 (low in 42.4%, intermediate in 35.3%, and
high in 22.3%). The trial showed no significant difference
between the 2 treatment groups in the incidences of MACCE
and mortality at 2 and 5 years.35,36 At 5 years, there was no difference between the 2 groups for mortality (5.7% v 7.9% for
CABG; HR, 0.73 [95% CI 0.39-1.37], p = 0.32), MACCE
(17.5% v 14.3% for CABG; HR, 1.27 [95% CI 0.84-1.90],
p = 0.26), MI (2% v 1.7% for CABG; HR, 1.20 [95% CI 0.373.93], p = 0.76), stroke (0.7% v 0.7% for CABG; HR, 0.99
[95% CI 0.14-7.02] p = 0.99). However, there was a significantly increased rate of repeat revascularization in patients
undergoing PCI (13% v 7.3% for CABG; HR, 1.86 [95% CI
1.09-3.17], p = 0.020). In patients with CAD involving isolated
LM stenosis, the incidence of MACCE for patients undergoing
CABG was greater, albeit statistically insignificant, than PCI
(14.8% v 7.4%, HR, 0.48 [95% CI 0.09-2.47]; p = 0.37).
Out of 600 patients, 10-year follow-up was achieved in 288
(96%) patients randomized to PCI and 288 patients (96%) randomized to CABG, respectively.37 The primary outcomes of
MACCE events between PCI and CABG groups were 29.8% v
24.7% (HR with PCI v CABG, 1.25 [95% CI, 0.93-1.69]).
There were no significant differences in the secondary composite outcomes of death, MI, or stroke (18.2% v 17.5%; HR
1.00 [95% CI, 0.70-1.44]) and all-cause mortality (14.5% v
13.8%; HR 1.13 [95% CI, 0.75-1.70]) between the PCI and
CABG groups. Furthermore, the 10-year incidences of ischemia-driven target-vessel revascularization (16.1% v 8.0%; HR
1.98 [1.21-3.21]) and any revascularization (21.3% v 10.6%;
HR 2.04 [1.33-3.11]) were higher after PCI than after CABG.
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PCI patients with a high SYNTAX score had a higher rate of
ischemia-driven revascularization. In patients with isolated
involvement of the LM vessel, the incidence of MACCE in
PCI versus CABG was 15.1% v 14.9% (HR, 1.55 [95% CI
0.40-5.95]. The authors thus concluded that there was no significant difference in the primary outcome of MACCE
between PCI and CABG in patients with LMCA disease. However, due to a wide non-inferiority margin and a relatively
small sample size, the study had insufficient statistical power
to allow for a firm conclusion, and the results should, at best,
be considered hypothesis-generating.4,38
EXCEL Trial
One of the more exciting yet controversial debates in cardiology in recent times has been about the Evaluation of
XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial.39 The
prospective, open-label, noninferiority study, which was conducted at 126 centers in 17 countries around the world,
included 1,905 patients with stable or unstable angina with an
LM stenosis of 70% assessed visually, or 50%-to-70% determined by invasive or non-invasive methods, and a SYNTAX
score of 32. Some of the key exclusion criteria were: (1) PCI
of the left main trunk at any time prior to randomization, or
non-left main trunk within 1 year of randomization; (2) prior
CABG; (3) need for any concomitant cardiac surgery; (4)
inability to tolerate dual-antiplatelet therapy for 1 year; (5)
SYNTAX score 33; and (6) visually estimated LM reference
vessel diameter <2.25 mm or >4.25 mm.
Patients were randomized to PCI with Xience everolimuseluting stents (n = 948) or CABG (n = 957). PCI was performed with a goal of achieving complete revascularization of
all ischemic territories, with dual-antiplatelet therapy initiated
before the procedure and continued for a minimum of 1 year
thereafter. The use of intravascular ultrasonographic guidance
was strongly encouraged. While the use of heparin or bivalirudin was allowed for procedural anticoagulation, glycoprotein
IIb/IIIa inhibitors were discouraged. CABG, performed with
or without cardiopulmonary bypass, was done with the recommended use of epiaortic ultrasonography and transesophageal
ultrasonography, with aspirin being administered during the
perioperative period and clopidogrel (in accordance with the
local standard of care) during the follow-up period. The mean
age of patients was 66 years. The long-term results of the trial
recently were published.40 The trial displayed an interesting
temporal relationship of comparative outcomes. In the early
postprocedural phase (at 30 days), the primary composite endpoint of death, stroke, or MI occurred less frequently in the
PCI group in comparison to the CABG group (4.9% v 7.9%;
HR 0.61 [95% CI 0.42-0.88]; p = 0.008). Patients undergoing
PCI also had better outcomes in the individual components of
stroke (0.6% v 1.3% for CABG; HR, 0.50 [95% CI 0.191.32]), MI (3.9% v 6.3% for CABG; HR, 0.63 [95% CI 0.420.94], and ischemia-driven revascularization (0.6% v 1.4% for
CABG; HR, 0.46 [95% CI 0.17-1.21]. This likely represented
the invasiveness of cardiac surgery as compared to PCI.

However, this differential risk was attenuated between 30 days
and 12 months of follow-up, with the primary composite outcome occurring in 4.1% of PCI patients v 3.8% of CABG
patients (HR, 1.07 [95% CI 0.68-1.70]). PCI patients had a
lower stroke rate (0.5% v 0.8% for CABG; HR 0.71 [95% CI
0.22-2.23]) but a higher event rate for MI (1.7% v 1.1% for
CABG; HR 1.58 [95% CI 0.72-3.48]) and ischemia-driven
revascularization (6.4% v 3.1% for CABG; HR 2.10 [95% CI
1.34-3.30]) during this period. Thereafter, the curves again
were seen to diverge as the authors approached 5-year followup. At 5 years, the primary outcome was 22.0% v 19.2% in
PCI v CABG arms (95% CI 0.95-1.50; p = 0.13). This also
can be seen in the NOBLE trial, in which, at 1 year, there were
more deaths in the surgical arm than the PCI (17 with CABG v
9 with PCI). The longer-term results, however, showed a
catch-up phenomenon, with 54 deaths in the PCI group and 50
in the CABG group. Analyzing the individual results of the
EXCEL trial, there was noted to be significantly higher allcause mortality in the PCI arm (9.9% v 13.0% with PCI; odds
ratio [OR] 1.38, 95% CI 1.03-1.85). However, 18 of 30 excess
deaths in the PCI group were adjudicated as noncardiovascular
deaths, and only 5 were cardiovascular deaths, with the rest
being of unknown cause. These results were in line with the
NOBLE trial, in which the risk of death at 5 years was similar
in the PCI and CABG arm. Of note, the incidences of stroke
and MI did not differ between the groups. It was, however,
noted that concordant with prior data, ischemia-driven revascularization was higher at 5 years in the PCI group. Longerterm results from the EXCEL trial are awaited and will help
guide future revascularization decisions.
NOBLE Trial
The Nordic-Baltic-British left main revascularization study
(NOBLE) was a multicenter, prospective, randomized, noninferiority trial done across 36 centers in Europe. This trial
included 1,184 patients with stable angina, unstable angina, or
non-ST-elevation MI and randomized them to receive either
CABG or PCI with biolimus-eluting biodegradable stents.4
Patients with more than 3 additional coronary lesions or more
complex coronary lesions, or considered at too high risk for
CABG or PCI or with ST-elevation MI within 24 hours, and
expected survival of less than 1 year, were excluded. The trial
provided a direct comparison of the outcomes of patients with
LM disease with different complexities treated either with
CABG or with PCI. All patients, irrespective of their SYNTAX score (high, medium, or low), were included and treated
with the intention of achieving complete revascularization of
all vessels with significant lesions. While only patients with
acute coronary syndrome in the CABG group received 75 mg
of clopidogrel daily for 12 months, all patients in the PCI
group received 75 mg of clopidogrel daily for 12 months.
Treatment also included lifelong 75-to-150 mg of aspirin. It
was hypothesized that PCI would produce no more inferior
clinical outcomes than CABG in patients with unprotected
LMCAD.41 The primary endpoint was a composite of MACCE
(death of any cause, nonprocedural MI repeat
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revascularization, and stroke). Patients in both the treatment
groups had similar age (66.2 years) and SYNTAX scores (22.4
in the PCI group and 22.3 in the CABG group). Even though
the MACCE rates were similar between the 2 groups at 1 year
(42 [7%] v 42 [7%]; 95% CI 2.9 to 2.9, p = 1.00), differences
were evident after the first 12 months following the intervention. At 5 years,42 rates of MACCE were higher with PCI
(28% v 19% with CABG; p = 0.0002), and exceeded the noninferiority threshold [HR 1.58 (95% CI 1.24-2.01)], and was significant for superiority of CABG compared with PCI
(p = 0.0044). All-cause mortality and cardiac death were similar after the 2 procedures (9% for both CABG and PCI; (HR
1.08, 95% CI 0.74-1.59; p = 0.68). However, patients treated
with CABG had lower rates of nonprocedural MI (3% v 8%
with PCI; p = 0.0002) and repeat revascularization (10% v
17% with PCI). SYNTAX score was not associated with
adverse outcomes after PCI compared to CABG.30,43
Despite the fact that the patient population was largely similar between the NOBLE and EXCEL trials and the fact that
both trials used second-generation drug-eluting stents, the 2
trials provided contradicting conclusions.26 While the NOBLE
trial showed that CABG was superior to PCI in the treatment
of LM disease, the EXCEL trial reported noninferiority of PCI
to CABG for the primary composite endpoint of MACCE. Of
note, “repeat revascularization” was not a part of the composite of the primary outcome in the EXCEL trial. Moreover, the
NOBLE trial included nonprocedural MI in preference to periprocedural MI used by other trials.
Summarized and tabulated trial data are shown in Table 2.

Retrospective Randomized Data
IRIS MAIN Study
In a retrospective observational study from the Left MAIN
Revascularization (IRIS-MAIN) registry, the authors reported
similar long-term risk of the composite primary outcomes of
death, MI, or stroke between CABG and PCI.44 The study
adopted an “all-comers” design and included all consecutive
Asian patients with significant unprotected LMCAD (defined
as stenosis of >50%) undergoing either CABG or PCI without
any concomitant valvular or aortic surgery. Out of 3,504
included patients, the primary outcome occurred in 7.5%
patients in the PCI group v 11.9% patients in the CABG group
(HR: 0.66; 95% CI 0.56-0.79; p < 0.001) at the end of 3 years.
Even though the authors reported similar risks of the primary
outcome in a propensity-matched cohort (PCI v CABG 9.6% v
9.9%; HR: 0.94; 95% CI: 0.77-1.15; p = 0.54), they found that
the risks for MI (HR: 2.11; 95% CI: 1.16-3.83; p = 0.01) and
repeat revascularization (HR: 5.95; 95% CI: 3.94-8.98; p
<.001) were significantly higher in the PCI group. The findings from this study were consistent with that of the PRECOMBAT, SYNTAX, and EXCEL trials. However, this study
was from a multicentric registry that did not allow for the consideration of variables, such as SYNTAX score and patient
frailty during analysis of outcomes.
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MAIN COMPARE Registry
The 10-year results of the MAIN-COMPARE registry were
presented at the Transcatheter Therapeutics meeting in San
Diego.45 The 3-year and 5-year results of this observational
study from the MAIN-COMPARE (Revascularization for
Unprotected Left Main Coronary Artery Stenosis: Comparison
of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry have been previously published.46,47
Briefly, the MAIN-COMPARE registry included patients with
unprotected LMCAD (stenosis >50%) who underwent PCI or
CABG at 12 major centers in Korea between January 2000
and June 2006. Exclusion criteria were patients with prior
CABG, concomitant valvular or aortic surgery, or ST-segment
elevation MI. During a 5-year follow-up, stenting was reported
to have similar rates of mortality (HR 1.13; 95% CI: 0.881.44, p = 0.35) and of the composite of death, Q-wave MI, or
stroke (HR: 1.07; 95% CI: 0.84-1.37, p = 0.59) but higher rates
of target vessel revascularization (HR: 5.11; 95% CI: 3.527.42, p < 0.001) than CABG in patients with unprotected
LMCAD. The authors further reported the 10-year outcomes
of patients, with a loss of only 1.3% of patients to follow-up.
There was again no significant difference in the unadjusted
cumulative incidences of all-cause death and all-cause death,
MI, or stroke between PCI and CABG after 10 years of revascularization (respectively, 21.1% v 23.2%; p = 0.23 and 23.8%
v 26.3%; p = 0.13). Target vessel revascularization was lower
after surgery compared with PCI (21.1% v 5.8%; p < 0.001).
The results remained largely unchanged after propensity
matching with similar risk of all-cause death and all-cause
death, MI, or stroke between treatment groups within 5 years
from index revascularization and from 5 to 10 years (0-5 years:
HR 1.10, 95% CI 0.82-1.47; p = 0.53; 5-10 years: HR 1.09,
95% CI 0.87-1.36; p = 0.48; and 0-5 years: HR 0.98, 95% CI
0.75-1.29; p = 0.91; 5-10 years: HR 1.16, 95% CI 0.93-1.43;
p = 0.19). However, when patients treated with DES were
compared with the CABG patients, an excess of mortality and
all-cause death, MI, or stroke from 5 to 10 years from index
procedure was observed (respectively, HR 1.35, 95% CI 1.001.81; p = 0.05 and HR 1.46, 95% CI 1.10-1.94; p = 0.009).
Therefore, the study did not observe any significant difference
in the outcomes of mortality and a composite of death, Qwave MI, or stroke between PCI and CABG up to 10 years.
However, the results clearly showed a benefit of CABG over
PCI with DES on mortality and a composite of death, Q-wave
MI, or stroke after 5 years.
Meta-analyses
Several meta-analyses evaluating the outcomes of patients
with LMCAD undergoing CABG and PCI have been published with differing conclusions.48-54 A 2016 study analyzing
the 5-year results of the PRECOMBAT and SYNTAX trials
found that PCI was associated with significantly higher
MACCE than CABG at 5 years (28.3% v 23.0%, p = 0.045).48
In patients with isolated LM or LM with additional 1-vessel
disease, PCI was associated with a 60% reduction in all-cause
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Table 2
Summary of Trials With the Longest Follow-Up
SYNTAX Trial29
PCI

Number of patients

Mean age, y
SYNTAX Score
Type of Stent

10 years
Multicenter
(North America, Europe)
Total patients
Total patients
followed up for
followed up
10 years (N = 848
for 10 years
LMCAD
(N = 841)
(N = 348)
LMCAD (N
=357)
65.2
65
28.4
29.1
First-generation, Paclitaxel-eluting stent

PCI

CABG

5 years
North European countries

EXCEL Trial40
PCI

CABG

PRECOMBAT Trial45
PCI

CABG

PCI

CABG

5 years
Multicenter (North America, Europe,
others)
948
957

300

66.0 § 9.6
65.9 § 9.5
20.6 § 6.2
20.5 § 6.1
Everolimus-eluting stents

61.8 § 10.0
62.7 § 9.5
24.3 § 9.6
25.3 § 10.9
Sirolimus-eluting stents

60.6 § 10.5
61.3 § 8.4
25.2 § 8.7
24.7 § 6.8
Drug-eluting stents (if reference diameter
<3.8 mm), bare-metal stents (if diameter
3.8 mm)

Composite of death from any cause,
MACCE (all-cause mortality, nonstroke or myocardial infarction
procedural myocardial infarction, repeat
revascularization, or stroke assessed after
5 years)
PCI 28% v CABG 19%
PCI 22% v CABG 19.2%
(HR 1.58 [95% CI 1.24-2.01]; p = 0.0002)
(HR 1/.10 [95% CI 0.95-1.50])

Major adverse cardiac or cerebrovascular
events

Left ventricular ejection fraction

PCI 29.8% v CABG 24.7%
(HR 1.25 [95% CI 0.93-1.69]

54.9 § 8.3%

(165/592)
(110/592)
PCI 9% v CABG 9%
(HR 1.08 [95% CI 0.74-1.59]; p = 0.68)
(54/592)
(50/592)
PCI 4% v CABG 2%
(HR 1.75 [95% CI 0.86-3.55]; p = 0.11)
(21/592)
(12/592)
PCI 17% v CABG 10%
(HR 1.73; [95% CI 1.25-2.40];
p = 0.0009)
(97/592)
(58/592)
PCI 8% v CABG 3%
(HR 2.99; [95% CI 1.66-5.39];
p = 0.0002)
(43/592)
(15/592)

(203/948)
(176/957)
PCI 13% v CABG 9.9%
(HR 1.38 [95% CI 1.03-1.85])
(119/948)
(89/957)
PCI 2.9% v CABG 3.7%
(HR 0.78 [95% CI 0.46-1.31])
(26/948)
(33/957)
PCI 17.2% v CABG 10.5%
(HR 1.79 [95% CI 1.36-2.36])

(87/300)
(72/300)
PCI 14.5% v CABG 13.8%
(HR 1.13 [95% CI 0.75-1.70])
(42/300)
(40/300)
PCI 1.9% v CABG 2.2%
(HR 0.71 [95% CI 0.22-2.23])
(5/300)
(6/300)
PCI 21.3% v CABG 10.6%
(HR 2.04 [95% CI 1.33-3.11])

(153/948)
(92/957)
PCI 10.6% v CABG 9.1%
(HR 1.14 [95% CI 0.84-1.55])

(59/300)
(29/300)
PCI 3.2% v CABG 2.8%
(HR 0.76 [95% CI 0.32-1.82])

(95/948)

(9/300)

592

592

66.2 years (IQR 9.9) 66.2 years (IQR 9.9)
22 (SD 8)
22 (SD 7)
New generation umirolimus-eluting stent

10 years
Hospitals in Korea

Le MANS Trial33

300

10 years
Multicenter
(United States, Poland)
52 (23 followed up
53 (23 followed up
for 10 years)
for 10 years)

Outcomes
All-cause death
Primary outcome

PCI 26.6% v CABG 28.2%
HR 0.92 (95% CI 0.69-1.22),
p = 0.023)
(95/357)
See above

(98/348)
See above

-

-

-

-

-

-

Death

Stroke

Repeat
revascularization

Myocardial
infarction

(84/957)

49.8 § 10.3%

PCI 21.6% v CABG 30.2%
(HR 1.55 [95% CI 0.71-3.39]; p = 0.26)
PCI 4.3% v CABG 6.3%
(HR 2.85 [95% CI 0.40-20.4]; p = 0.29)
PCI 26.1% vs. CABG 31.3%
(HR 1.34 [95% CI 0.61-2.95]; p = 0.46)

PCI 8.7% v CABG 10.4%
(HR 1.14 [95% CI 0.30-4.25]; p = 0.83)

(8/300)

Abbreviations: CABG, coronary artery bypass grafting; CI, confidence interval; EXCEL, Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization; HR,
hazard ratio; IQR, interquartile range; LE MANS, Left Main Coronary Artery Stenting; LMCAD, left main coronary artery disease; MACCE, major adverse cardiovascular and cerebrovascular event; NOBLE,
Nordic-Baltic-British left main revascularization study; PCI, percutaneous coronary intervention; PRECOMBAT, Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using SirolimusEluting Stent in Patients with Left Main Coronary Artery Disease; SD, standard deviation; SYNTAX, Synergy between Percutaneous Coronary intervention with TAXUX and Cardiac surgery; TIMI, thrombolysis
in myocardial infarction.

S. Shekhar et al. / Journal of Cardiothoracic and Vascular Anesthesia 36 (2022) 33703378

Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on September 21, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Longest follow-up
Region

CABG

NOBLE Trial42

S. Shekhar et al. / Journal of Cardiothoracic and Vascular Anesthesia 36 (2022) 33703378

mortality (HR, 0.40; 95% CI 0.20-0.83; p = 0.029) and a 67%
reduction in cardiac mortality (HR, 0.33; 95% CI 0.12-0.88;
p = 0.025) when compared to CABG.26 These results are in
line with previously published literature.53,54 Other studies
have shown comparable outcomes in patients undergoing PCI
and CABG.49 A pooled analysis from 11 randomized trials
found that the 5-year all-cause mortality was similar for
patients with LMCAD undergoing PCI and CABG (10.7%
after PCI v 10.5% after CABG; HR 1.07 [95% CI 0.87-1.33;
p = 0.52]), regardless of diabetes status.50 Another meta-analysis51 looking at the 5-year outcomes of patients with unprotected LM disease concluded that there was no significant
difference between PCI and CABG in all-cause (OR 0.93,
[95% CI 0.71-1.21]) and cardiovascular mortality. Patients
undergoing CABG had a reduced risk of MI, revascularization,
and MACCE. More recently, Ahmad et al published the results
of their meta-analysis52 evaluating the results from all the trials comparing CABG and PCI. The study included the 1-year
results from the study by Boudriot,55 the 5-year results of the
NOBLE,42 EXCEL,40 and PRECOMBAT35 trials, and the 10year results from the SYNTAX trial.29 The mean follow-up
duration was 67.1 months. The authors reported no significant
differences between PCI and CABG for all-cause mortality
(relative risk [RR] 1.03, [95% CI 0.81-1.32]; p = 0.779), cardiac death (RR 1.03, [95% CI 0.79-1.34]; p = 0.817), MI (RR
1.22, [95% CI 0.96-1.56]; p = 0.110) and stroke (RR 0.74,
[95% CI 0.35-1.50]; p = 0.400). There was noted to be an
increased risk of unplanned revascularization associated with
PCI (RR 1.73, [95% CI 1.49-2.02]; p < 0.001).
Conclusion
CABG and PCI are both complimentary revascularization
strategies for patients with stable LMCA disease. Individualized decision-making is needed considering the coronary anatomy, SYNTAX score, presence of co-existing cardiac and
non-cardiac medical conditions, as well as patient preference.
The involvement of a multidisciplinary team (or the Heart
Team), including cardiac surgeons, interventional cardiologists, anesthesiologists, and cardiac imaging specialists, is paramount in decision-making.
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